Phenotypic and genetic characterization of MERS coronaviruses from Africa to understand their zoonotic potential.
Africa
MERS-CoV
characterization
coronaviruses
phenotype
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
22 06 2021
22 06 2021
Historique:
entrez:
8
6
2021
pubmed:
9
6
2021
medline:
16
6
2021
Statut:
ppublish
Résumé
Coronaviruses are pathogens of pandemic potential. Middle East respiratory syndrome coronavirus (MERS-CoV) causes a zoonotic respiratory disease of global public health concern, and dromedary camels are the only proven source of zoonotic infection. More than 70% of MERS-CoV-infected dromedaries are found in East, North, and West Africa, but zoonotic MERS disease is only reported from the Arabian Peninsula. We compared viral replication competence of clade A and B viruses from the Arabian Peninsula with genetically diverse clade C viruses found in East (Egypt, Kenya, and Ethiopia), North (Morocco), and West (Nigeria and Burkina Faso) Africa. Viruses from Africa had lower replication competence in ex vivo cultures of the human lung and in lungs of experimentally infected human-DPP4 (hDPP4) knockin mice. We used lentivirus pseudotypes expressing MERS-CoV spike from Saudi Arabian clade A prototype strain (EMC) or African clade C1.1 viruses and demonstrated that clade C1.1 spike was associated with reduced virus entry into the respiratory epithelial cell line Calu-3. Isogenic EMC viruses with spike protein from EMC or clade C1.1 generated by reverse genetics showed that the clade C1.1 spike was associated with reduced virus replication competence in Calu-3 cells in vitro, in ex vivo human bronchus, and in lungs of hDPP4 knockin mice in vivo. These findings may explain why zoonotic MERS disease has not been reported from Africa so far, despite exposure to and infection with MERS-CoV.
Identifiants
pubmed: 34099577
pii: 2103984118
doi: 10.1073/pnas.2103984118
pmc: PMC8237650
pii:
doi:
Substances chimiques
Spike Glycoprotein, Coronavirus
0
DPP4 protein, human
EC 3.4.14.5
Dipeptidyl Peptidase 4
EC 3.4.14.5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI151810
Pays : United States
Informations de copyright
Copyright © 2021 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
Competing interest statement: Together with other global opinion leaders, M.P. and K.S. coauthored a perspectives article on optimizing the use of the ferret experimental model for research on influenza [J. A. Belser et al. Emerg. Infect. Dis. 24, 965–971 (2018)].
Références
Antiviral Res. 2018 Nov;159:63-67
pubmed: 30261226
Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9864-9
pubmed: 27528677
N Engl J Med. 2014 Aug 28;371(9):828-35
pubmed: 25162889
Viruses. 2012 Jun;4(6):1011-33
pubmed: 22816037
Nature. 2020 Jul;583(7815):282-285
pubmed: 32218527
Euro Surveill. 2019 Nov;24(48):
pubmed: 31796154
J Virol Methods. 2016 Oct;236:178-183
pubmed: 27459876
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5
pubmed: 16169905
Emerg Infect Dis. 2017 Jul;23(7):1079-1084
pubmed: 28585916
N Engl J Med. 2014 Jun 26;370(26):2499-505
pubmed: 24896817
MMWR Morb Mortal Wkly Rep. 2016 Feb 19;65(6):163-4
pubmed: 26890816
J Virol. 2005 Feb;79(3):1595-604
pubmed: 15650185
J Virol. 2010 Apr;84(7):3134-46
pubmed: 19906932
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Osong Public Health Res Perspect. 2015 Aug;6(4):269-78
pubmed: 26473095
Euro Surveill. 2018 Aug;23(32):
pubmed: 30107872
Lancet Planet Health. 2019 Dec;3(12):e521-e528
pubmed: 31843456
mBio. 2018 Oct 30;9(5):
pubmed: 30377284
Emerg Infect Dis. 2016 Jun;22(6):1086-9
pubmed: 27071076
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):E3119-E3128
pubmed: 28348219
Lancet Infect Dis. 2021 Mar;21(3):385-395
pubmed: 33035474
Lancet Respir Med. 2014 Oct;2(10):813-22
pubmed: 25174549
Epidemiol Infect. 2019 Jan;147:e84
pubmed: 30869000
Emerg Microbes Infect. 2016 Dec 21;5(12):e126
pubmed: 27999426
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382915
Nat Med. 2004 Dec;10(12 Suppl):S88-97
pubmed: 15577937
Eur Respir J. 2017 Mar 8;49(3):
pubmed: 28275173
Euro Surveill. 2013 Sep 05;18(36):pii=20574
pubmed: 24079378
Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3144-3149
pubmed: 29507189